Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)
Phase 2
Terminated
- Conditions
- LV MicrocableLV LeadLV TherapyLV Treatment
- Registration Number
- NCT01731210
- Lead Sponsor
- LivaNova
- Brief Summary
The LENEA study is an international, prospective, open label, non-randomized multicenter clinical research study designed to assess the safety and effectiveness of the NANO LV lead system.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
- Approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D system for treatment of heart failure or life threatening ventricular tachyarrhythmia(s)
- Receiving a new implant OR undergoing an upgrade from an existing ICD or pacemaker implant with no prior implanted LV lead OR undergoing a new LV implant attempt consecutive to a recent LV lead placement failure not related to coronary sinus cannulation failure
- Patient receiving the PARADYM RF CRT or PARADYM RF CRT SONR devices
- Ability to provide informed consent for study participation and is willing and able to comply with the prescribed follow-up tests and schedule of evaluations
Exclusion Criteria
- Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;
- Incessant Ventricular tachyarrhythmias;
- Unstable angina, or acute MI , CABG , or PTCA within the past 4 weeks;
- Correctable valvular disease that is the primary cause of heart failure;
- Post heart transplant (patients who are waiting for a heart transplant are allowed in the study);
- Patient who had previously a permanently implanted LV lead;
- Concurrent implant with another pacemaker or ICD (previously implanted pacemaker or ICD devices should be removed prior to implant with the Paradym RF CRT-D or Paradym RF CRT SONR);
- Already included in another clinical study that could confound the results of this study;
- Life expectancy less than 1 year.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Freedom from left ventricular lead related complications through 1 month 1 month
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Charles Nicolle
🇫🇷Rouen, France